Skip to main content

Table 3 Non-fasting blood sugar, HbA1c, insulin, and lipids in SHRcp fed empagliflozin-containing diet or control diet for 10 weeks

From: Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

  Control (n = 11–12) SGLT2 (n = 12)
Non-fasting blood sugar (mg/dl) 227 ± 17 140 ± 6*
HbA1c (%) 1.30 ± 0.03 1.12 ± 0.02*
Insulin (ng/mL) 103.6 ± 12.2 22.4 ± 2.4*
Total cholesterol (mg/dL) 206 ± 6 207 ± 9
Triglyceride (mg/dL) 591 ± 51 812 ± 39*
Free fatty acid (mmol/L) 0.46 ± 0.03 0.48 ± 0.02
  1. Control SHRcp fed control diet; SGLT2 SHRcp fed control diet containing empagliflozin. Values are mean ± SEM. Statistical analysis was performed by unpaired Student’s t test
  2. * P < 0.01 versus control